Sun, B.B.* ; Chiou, J.* ; Traylor, M.* ; Benner, C.* ; Hsu, Y.H.* ; Richardson, T.G.* ; Surendran, P.* ; Mahajan, A.* ; Robins, C.* ; Vasquez-Grinnell, S.G.* ; Hou, L.* ; Kvikstad, E.M.* ; Burren, O.S.* ; Davitte, J.* ; Ferber, K.L.* ; Gillies, C.E.* ; Hedman, A.K.* ; Hu, S.* ; Lin, T.* ; Mikkilineni, R.* ; Pendergrass, R.K.* ; Pickering, C.* ; Prins, B.* ; Baird, D.* ; Chen, C.Y.* ; Ward, L.D.* ; Deaton, A.M.* ; Welsh, S.* ; Willis, C.M.* ; Lehner, N. ; Arnold, M. ; Wörheide, M. ; Suhre, K.* ; Kastenmüller, G. ; Sethi, A.* ; Cule, M.* ; Raj, A.* ; Kang, H.M.* ; Burkitt-Gray, L.* ; Melamud, E.* ; Black, M.H.* ; Fauman, E.B.* ; Howson, J.M.M.* ; McCarthy, M.I.* ; Nioi, P.* ; Petrovski, S.* ; Scott, R.A.* ; Smith, E.N.* ; Szalma, S.* ; Waterworth, D.M.* ; Mitnaul, L.J.* ; Szustakowski, J.D.* ; Gibson, B.W.* ; Miller, M.R.* ; Whelan, C.D.*
Plasma proteomic associations with genetics and health in the UK Biobank.
Nature 622, 329-338 (2023)
The Pharma Proteomics Project is a precompetitive biopharmaceutical consortium characterizing the plasma proteomic profiles of 54,219 UK Biobank participants. Here we provide a detailed summary of this initiative, including technical and biological validations, insights into proteomic disease signatures, and prediction modelling for various demographic and health indicators. We present comprehensive protein quantitative trait locus (pQTL) mapping of 2,923 proteins that identifies 14,287 primary genetic associations, of which 81% are previously undescribed, alongside ancestry-specific pQTL mapping in non-European individuals. The study provides an updated characterization of the genetic architecture of the plasma proteome, contextualized with projected pQTL discovery rates as sample sizes and proteomic assay coverages increase over time. We offer extensive insights into trans pQTLs across multiple biological domains, highlight genetic influences on ligand–receptor interactions and pathway perturbations across a diverse collection of cytokines and complement networks, and illustrate long-range epistatic effects of ABO blood group and FUT2 secretor status on proteins with gastrointestinal tissue-enriched expression. We demonstrate the utility of these data for drug discovery by extending the genetic proxied effects of protein targets, such as PCSK9, on additional endpoints, and disentangle specific genes and proteins perturbed at loci associated with COVID-19 susceptibility. This public–private partnership provides the scientific community with an open-access proteomics resource of considerable breadth and depth to help to elucidate the biological mechanisms underlying proteo-genomic discoveries and accelerate the development of biomarkers, predictive models and therapeutics1.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Abo Blood-group; Deficiency; Proteins; Cohort; Risk
Keywords plus
Language
english
Publication Year
2023
Prepublished in Year
0
HGF-reported in Year
2023
ISSN (print) / ISBN
0028-0836
e-ISSN
1476-4687
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 622,
Issue: 7982,
Pages: 329-338
Article Number: ,
Supplement: ,
Series
Publisher
Nature Publishing Group
Publishing Place
London
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30205 - Bioengineering and Digital Health
Research field(s)
Enabling and Novel Technologies
PSP Element(s)
G-503891-001
Grants
leading internal activities at Olink
Janssen Pharmaceutical Companies of Johnson Johnson
Genentech
Copyright
Erfassungsdatum
2023-10-18